G1T38 is a potential best-in-class oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. Preclinical data presented at the American Association for Cancer Research 2016 Annual Meeting and published in Molecular Cancer Research and Oncotarget demonstrated G1T38’s differentiation from other CDK4/6 inhibitors in development.

G1T38 is currently being evaluated in two Phase 1/2 clinical trials: a trial in combination with Faslodex® for patients with estrogen receptor-positive, HER2-negative breast cancer (NCT02983071), and a trial in combination with Tagrisso® in EGFRm non-small cell lung cancer (NCT03455829).